6649 Associations of Fibroscan Results with Body Composition and Laboratory Measures in Patients with Obesity and Inflammation

Abstract Disclosure: A. Lyman: None. E. Nwosu: None. H.K. Gopalakrishna: None. Y. Rotman: None. N. Abdul Majeed: None. J. Lazareva: None. S.M. Brady: None. A.P. Demidowich: Grant Recipient; Self; Dexcom, Inc. J.A. Yanovski: Grant Recipient; Self; Soleno Therapeutics (DCCR), Rhythm Pharmaceuticals (setmelanotide), Hikma Pharmaceuticals (colchicine), Versanis Bio (bimagrumab. Background: Obesity and inflammation are believed to contribute to hepatic dysfunction and risk for metabolic dysfunction-associated steatohepatitis (MASH). Fibroscan (Echosens) can non-invasively quantify liver fat content (LFC) by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) by transient elastography as a surrogate for fibrosis. Other surrogate markers for liver fibrosis include Fibrosis-4 (FIB-4) and the AST-to-Platelet Ratio Index (APRI) indices. Central obesity is a stronger predictor of MASH than appendicular fat. It is unknown whether the associations between these measures hold in a population with obesity and inflammation. Hypotheses: We hypothesized that LFC and LSM would be positively associated with Body Mass Index (BMI), central obesity (trunk), but not appendicular fat percentage, as well as with HOMA-IR, hs-CRP, and both FIB-4 and APRI indices in patients with obesity and inflammation. Methods: A convenience sample of adult participants with BMI ≥30 kg/m2 and hs-CRP ≥2.0 mg/L in a clinical trial (n=38) underwent body composition by DXA, Fibroscan, and fasting blood sampling for glucose, insulin, hs-CRP, AST, ALT, and platelets, all on the same day. LSM results were considered valid if the interquartile range for > 10 measurements was ≤30%. ANCOVA analysis was used to examine associations between these parameters. Results: The cohort had a mean age=48 years (SD=12.5 years), BMI=39.3 kg/m2 (SD=6.0 kg/m2,), CAP=296.0 dB/m (SD=54.0 dB/m), LSM=5.9 kPa (SD=2.4 kPa), hs-CRP=7.2 mg/L (SD=6.1 mg/L), HOMA-IR=5.9 (SD=4.5), FIB-4=0.80 (SD=0.33), and APRI=0.24 (SD=0.11). Using univariate linear regression analysis, we found CAP to be positively associated with increased trunk body fat % (p=0.009, partial η2=0.202) and BMI (p=0.006, partial η2=0.195) independent of sex. Similarly, LSM was positively correlated with increased trunk body fat % (p=0.047, partial η2=0.125), APRI (p=0.025, partial η2=0.156), and log-transformed HOMA-IR (p=0.018, partial η2=0.150). We did not observe significant associations between hs-CRP, FIB-4 or appendicular body fat % with CAP or LSM in our population. Conclusion: As hypothesized, measures of liver fat content and fibrosis by Fibroscan CAP and LSM were positively associated with body composition (predominantly trunkal fat), measures of insulin resistance, and laboratory indices of hepatic fibrosis and steatosis in people with obesity and inflammation. Presentation: 6/3/2024